Food and Drug Administration
Peripheral and Central Nervous System Advisory
Committee
Slides
Disclaimer
The statements contained in this document(s) are those of the product’s sponsor, not FDA, and FDA does not necessarily agree with the sponsor’s statemtns. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Aggrenox™, Manfred Haehl, M.D.
Boehringer
Ingelheim Pharmaceuticals, Inc.
Clinical Overview, Gregory W. Albers, M.D.
Aggrenox™ Development Rationale, Thomas Müller, M.D.,
Ph.D.
Clinical Trial Efficacy,
Boehringer Ingelheim Pharmaceuticals, Inc.
Aggrenox™ Safety, Kenneth Rakowski, M.D.
Boehringer Ingelheim Pharmaceuticals, Inc.
Conclusion, Manfred Haehl, M.D.
Boehringer Ingelheim Pharmaceuticals, Inc.